Keyphrases
AIDS/HIV
13%
Antibiotic Use
8%
Atazanavir
13%
Clinical Features
10%
Colchicine
13%
Collection Site
6%
Confidence Interval
19%
COVID-19
49%
COVID-19 Impact
6%
COVID-19 Patients
20%
Diagnostic Accuracy
7%
Disability
6%
Drug Delivery Platform
6%
Early Treatment
8%
Ecuador
8%
Efavirenz
13%
Embase
7%
Epidemiological Characteristics
8%
Epidemiological Situation
7%
Hemoglobin
7%
Hospitalized COVID-19 Patients
7%
Hospitalized Patients
10%
Hydroxychloroquine
26%
Inverse Variance
8%
Length of Hospital Stay
10%
Lipid Profile Levels
13%
Mean Platelet Volume
13%
Mental Health
7%
Meta-analysis
82%
Meta-analysis of Randomized Controlled Trials
13%
Monkeypox
13%
Mortality Prediction
13%
Neonate
13%
Neutrophil-to-lymphocyte Ratio
6%
Observational Research
7%
Patients with COVID-19
27%
Peru
20%
Platelets
7%
Post-acute
6%
Pregnant Women
8%
PubMed
11%
Random Effects Model
8%
Randomized Controlled Trial
21%
Risk of Bias
9%
Risk Ratio
8%
Scopus
8%
Sepsis
16%
Systematic Meta-analysis
94%
Virus Infection
7%
Web of Science
8%
Medicine and Dentistry
Abscess
8%
Acute Graft Versus Host Disease
6%
Agents Acting on the Eye
6%
Antibiotics
10%
Antiviral Therapy
6%
Apixaban
13%
Atazanavir
13%
Cat-Scratch Disease
6%
Cohort Analysis
20%
COVID-19
57%
Dalteparin Sodium
13%
Depression
6%
Diagnostic Accuracy
7%
Disease
17%
Docking (Molecular)
6%
Efavirenz
13%
Family Health
6%
First Trimester Pregnancy
6%
Gingival Recession
6%
Health Survey
7%
HIV/AIDS
8%
Human Immunodeficiency Virus
9%
Human Leukocyte Antigen
6%
Infection
22%
Intensive Care Unit
9%
Kidney Denervation
6%
Kidney Injury
6%
Leishmania
6%
Leishmania donovani
6%
Major Bleeding
6%
Malignant Neoplasm
8%
Mean Platelet Volume
6%
Meta-Analysis
60%
Mixed Infection
13%
Monkeypox
26%
Neonate
6%
Neutrophil
6%
Odds Ratio
9%
Prematurity
10%
Prevalence
21%
Reinfection
6%
Renal Artery
6%
Resistant Hypertension
6%
Sepsis
10%
Severe Depression
6%
Staphylococcus Aureus
6%
Systematic Review
100%
Tiprelestat
6%
Venous Thromboembolism
6%
Virus DNA
7%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
8%
Antibiotic Agent
8%
Antibiotics
6%
Antivirus Agent
7%
Apixaban
6%
Atazanavir
13%
Bacterial Infection
6%
Bleeding
6%
Chemotherapy
6%
Chloroquine
6%
Clinical Feature
7%
Cohort Study
14%
Colchicine
13%
Coronavirinae
20%
Cross-Sectional Study
17%
Dalteparin
13%
Diabetes Mellitus
6%
Disease
41%
Efavirenz
13%
Endothelial Dysfunction
6%
Heart Infarction
6%
HIV
9%
Hydroxychloroquine
26%
Hypercholesterolemia
6%
Hyperglycemia
6%
Hypernatremia
6%
Infection
29%
Kidney Injury
6%
Leishmania donovani
6%
Lipoprotein
6%
Malignant Neoplasm
6%
Mixed Infection
8%
Monkeypox
44%
Monkeypox Virus
7%
Mucocutaneous Lymph Node Syndrome
6%
Myocarditis
6%
Newborn Sepsis
6%
Observational Study
15%
Prevalence
17%
Procalcitonin
8%
Random Effects Model
11%
Randomized Clinical Trial
6%
Randomized Controlled Trial
30%
Reinfection
6%
Resistant Hypertension
6%
Sepsis
17%
Staphylococcus Aureus
6%
Triple Negative Breast Cancer
6%
Venous Thromboembolism
6%
Virus Infection
13%
